Manufacturers interested in marketing their innovative products in Hainan’s Pilot Zone can learn more by viewing our article “China Changes Clinical Data Requirements for Medical Device Registration”. Contact our team to learn more about innovative product marketing strategies throughout the SE Asia region.
Class III High Risk Medical Device List Adjusted
In August 2014, NMPA released a list of Class III high risk device list that would need NMPA approval prior to starting a clinical trial in China. Originally, there were 8 major items but in June of 2020, NMPA released a revised version, which reduced the list to 6 major product types.
The Class III product categories that require clinical trials in China include implantable cardiac rhythm management equipment, implantable ventricular assisting systems, implantable drug infusion equipment, artificial heart valves and intravascular stents, tissue engineering medical products containing live cells, and absorbable long bone internal fixation implantable devices.
Process for Class II Applications that are Later Confirmed as Class III Medical Devices During the Technical Review
For medical device applications that are originally applied for as Class II but are later identified as a Class III during the CMDE technical review, a rejection letter will be issued and the review process will be terminated. When the applicant resubmits the registration application as Class III medical device, the copy of the rejection letter will need to be included and the applicant will only need to pay the difference between Class III and Class II registration fees. To expedite time to market, it’s important to correctly classify your product up front.
Asia Actual has experienced personnel that can help determine the classification and even reach out to the NMPA for their feedback for novel products.